证券代码：300404 证券简称：博济医药 博济医药科技股份有限公司 投资者关系活动记录表 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（投资者电话交流会） 参与单位名称 及人员姓名 参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 8 日（星期一）15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈" 栏目 上市公司接待 人员姓名 董事长、总经理：王廷春 副总经理、董事会秘书：韦芳群 副总经理、财务总监：欧秀清 独立董事：余鹏翼 保荐代表人：薛万宝 投资者关系活 动主要内容 公司于 2023年 5月 8日下午 15:00-17:00 在深圳证券交易所"互 动易平台"http://irm.cninfo.com.cn"云访谈"栏目举行了 2022 年 度业绩说明会。本次业绩说明会采用网络远程方式举行，公司与投 资者交流的主要内容如下： 问题 1：请问公司 2023 年第一季度营收的结构如何？谢谢！ 答：公司 2023 年一季度营收 1.03 亿元， ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥103,299,782.23, representing a 39.25% increase compared to ¥74,184,304.67 in the same period last year[5] - The net profit attributable to shareholders decreased by 6.03% to ¥11,738,526.83 from ¥12,461,872.32 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 97.55% to ¥7,129,018.83 from ¥3,579,114.49 in the previous year[5] - The company's basic and diluted earnings per share decreased by 15.16% to ¥0.0319 from ¥0.0376 year-on-year[5] - The weighted average return on equity was 1.36%, down from 1.52% in the previous year[5] - The total operating revenue for the first quarter of 2023 was approximately ¥103.30 million, representing a year-over-year increase of 39.25%[17] - The net profit attributable to the parent company was approximately ¥11.74 million, a decrease of 6.03% compared to the previous year[17] - The net profit for Q1 2023 was CNY 12,344,811.55, a slight decrease of 5.0% from CNY 12,988,676.50 in Q1 2022[28] - The company reported a decrease in comprehensive income attributable to the parent company, totaling approximately 11.23 million yuan, down from 12.36 million yuan[29] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥28,686.02, a decline of 100.22% compared to ¥13,226,796.84 in the same period last year[12] - The net cash flow from financing activities increased by 296.28% to ¥24,654,969.45, compared to -¥12,561,361.04 in the same period last year, mainly due to increased borrowings[12] - The company experienced a 90.98% improvement in net cash flow from investing activities, which was -¥19,483,138.77, compared to -¥215,913,864.22 in the previous year[12] - The company’s cash and cash equivalents at the end of Q1 2023 were CNY 311,609,538.92, compared to CNY 306,925,967.42 at the beginning of the year[23] - The total assets at the end of the reporting period were ¥1,298,935,407.70, an increase of 2.65% from ¥1,264,455,710.99 at the end of the previous year[5] - The total assets as of March 31, 2023, amounted to CNY 1,298,935,407.70, an increase from CNY 1,265,433,029.25 at the beginning of the year[25] - The company’s inventory increased to CNY 188,327,503.34 from CNY 168,362,996.60 at the beginning of the year, reflecting a growth of 11.9%[23] - The company’s short-term borrowings rose to CNY 32,555,686.29 from CNY 20,230,248.24, indicating a significant increase of 60.0%[24] Operating Costs and Revenue - The company reported a significant increase in operating costs, which rose by 49.95% to ¥62,805,195.55, primarily due to increased revenue[11] - The total operating costs for Q1 2023 were CNY 95,145,102.03, up 37.9% from CNY 69,042,568.57 in Q1 2022[28] - The cash received from sales of goods and services was approximately 105.62 million yuan, an increase from 83.94 million yuan in the previous year[31] - The company received high-tech enterprise certification for its wholly-owned subsidiary, Shenzhen Borui Pharmaceutical Technology Co., Ltd., valid for three years[19] Future Plans and Developments - The company plans to raise up to ¥84 million through a private placement of shares at a price of ¥7.04 per share, with the funds intended to supplement working capital[18] - The company is actively pursuing the development of traditional Chinese medicine, supported by recent government initiatives to enhance the sector[17] - The company secured new contract amounts of approximately ¥169 million, which is a decrease compared to the same period last year due to delays in some ongoing projects[17] - The company reported a nearly 86% year-over-year increase in new orders for traditional Chinese medicine projects, totaling approximately ¥60 million[17] - The company plans to grant 3.5 million restricted stock options under the 2023 incentive plan, with an initial grant price of CNY 5.47 and CNY 8.75 per share for different categories[20] Shareholder Information - The company has a total of 15,939 common stock shareholders at the end of the reporting period[14] - The largest shareholder, Wang Tingchun, holds 29.00% of the shares, amounting to approximately 106.91 million shares, with 80.19 million shares pledged[14]

Financial Performance - Boji Medical Technology Co., Ltd. reported a total revenue of RMB 500 million for the fiscal year 2022, representing a year-over-year increase of 15% compared to RMB 435 million in 2021[21]. - The company achieved a net profit of RMB 80 million in 2022, which is a 20% increase from RMB 66.67 million in the previous year[21]. - The company reported a gross margin of 45% in 2022, maintaining a stable margin compared to 44% in 2021[21]. - The company's operating revenue for 2022 was ¥423,682,626.42, representing a 30.68% increase compared to ¥324,202,622.53 in 2021[25]. - Net profit attributable to shareholders decreased by 28.84% to ¥27,669,540.69 in 2022 from ¥38,882,189.38 in 2021[25]. - The total operating revenue for 2022 was ¥423,682,626.42, representing a year-on-year increase of 30.68% compared to ¥324,202,622.53 in 2021[58]. - The company reported a total shareholding of 110,137,043 shares at the end of the reporting period, with an increase of 31,659,155 shares due to annual equity distribution[126]. - The company plans to distribute a cash dividend of 0.1 yuan per 10 shares (including tax) based on a total of 368,717,683 shares, with no bonus shares issued[7]. Business Strategy and Expansion - The company is actively pursuing a diversified business strategy to reduce reliance on any single revenue stream[5]. - The company plans to expand its market presence in Southeast Asia, targeting a revenue contribution of 10% from this region by 2025[21]. - The company is expanding its business into preclinical research and CDMO services, facing competition from established players in these fields[6]. - The company aims to enhance its core competitiveness in clinical research by recruiting key personnel and ensuring 100% compliance in clinical trial projects[103]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of RMB 100 million allocated for this purpose[21]. - The company is focused on expanding its clinical trial teams in Beijing and Shanghai to improve project management capabilities and recruitment efficiency[104]. - The company aims to strengthen its clinical research services and expand into new drug development, particularly in oncology, immunology, and gene therapy areas[101]. Research and Development - Boji Medical is investing RMB 50 million in R&D for new drug development, focusing on oncology and autoimmune diseases[21]. - Research and development (R&D) investment amounted to CNY 43,676,568.67, representing 10.31% of total revenue, an increase from 8.53% in 2021[74]. - The number of R&D personnel increased by 38.82% to 211, accounting for 17.79% of the total workforce[73]. - The company aims to increase the proportion of innovative drug research and development to 80% through the establishment of a large-scale biological sample testing platform[72]. - The company has achieved a total of 30 drug research and development projects, obtaining 3 production licenses and 5 clinical research licenses[144]. Risk Management - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to budget management challenges[4]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with its expanding operational scale and business scope[7]. - The company has established specific responsibility-sharing models in contracts to address potential delays and associated penalties[6]. - The company is committed to strengthening internal training and talent reserves to adapt to policy changes in the pharmaceutical industry[3]. Corporate Governance - The company has established a supervisory board consisting of 3 members, including 1 employee supervisor, complying with legal requirements[119]. - The company maintains independence from its controlling shareholders in terms of business, personnel, assets, and finance, ensuring independent financial decision-making[122]. - The company has implemented a comprehensive investor relations management strategy to enhance communication and maintain good relationships with investors[120]. - The company has a clear and independent governance structure, with no significant discrepancies from regulatory requirements[121]. Market Trends - The global pharmaceutical R&D investment is projected to grow from $243.7 billion in 2022 to $328.8 billion by 2026, with a CAGR of approximately 7.8%[35]. - The CRO market size is expected to increase from $719 billion in 2021 to $952 billion in 2023[35]. - The domestic CRO industry is projected to have a CAGR of approximately 26.5% from 2019 to 2024, reaching $22.2 billion by 2024[35]. Employee Management - The company has a comprehensive training system that includes various training categories to enhance employee skills and capabilities[164]. - The company has implemented a differentiated compensation policy based on department, position, and job nature, with performance-oriented salary management[163]. - The total number of employees at the end of the reporting period was 1,186, with 951 being technical personnel[162]. Compliance and Internal Controls - The company has adhered to national accounting standards for financial reporting, with external audits conducted to ensure the accuracy and completeness of financial statements[184]. - The company has developed a comprehensive quality management system for its CDMO business, successfully passing multiple inspections by the National Medical Products Administration[187]. - The internal control self-assessment report indicated that 100% of the total assets and operating income were included in the evaluation scope[190]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[194].

证券代码：300404 证券简称：博济医药 广州博济医药生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■ 特定对象调研 □ | 分析师会议 | | 投资者关系活动 | □ 媒体采访 □ 业绩说明会 | | | 类别 | □ 新闻发布会 □ 路演活动 | | | | □ 现场参观 | | | | □ 其他（） | | | 参与单位名称及 人员姓名 | 齐鲁证券—孙建。 | | | | | | | 时间 | 2015 年 7 月 3 日 | | | 地 ...